The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Combo Drug Offers New Hope Against Hepatitis C

January 17, 2014

This article was reported by Health Newsline.

Health Newsline reported on a study using a combination of two oral antiviral drugs -- daclatasvir and sofosbuvir -- to treat hepatitis C virus (HCV) infection. Mark Sulkowski, MD, medical director of the Johns Hopkins Center for Viral Hepatitis, and colleagues conducted a clinical trial to determine safety and efficacy of the combination drug treatment. The drug sofosbuvir (brand name Sovaldi), manufactured by Gilead Sciences, received US Food and Drug Administration approval in December, while daclatasvir is in the approval process.

The participants comprised 211 HCV patients at 18 medical centers in the United States and Puerto Rico. The participants received a daily combination of 60 milligrams of daclatasvir and 400 milligrams of sofosbuvir, with and without ribavirin. At 12 weeks, approximately 98 percent of patients had what doctors call a functional cure -- the treatment eliminated the virus and stopped it from replicating, even in patients who could not take or did not respond to current treatment.

View Full Article

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More on Hepatitis C Drugs in Development

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: